Cargando…

Faecal metabolome and its determinants in inflammatory bowel disease

OBJECTIVE: Inflammatory bowel disease (IBD) is a multifactorial immune-mediated inflammatory disease of the intestine, comprising Crohn’s disease and ulcerative colitis. By characterising metabolites in faeces, combined with faecal metagenomics, host genetics and clinical characteristics, we aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vich Vila, Arnau, Hu, Shixian, Andreu-Sánchez, Sergio, Collij, Valerie, Jansen, Bernadien H, Augustijn, Hannah E, Bolte, Laura A, Ruigrok, Renate A A A, Abu-Ali, Galeb, Giallourakis, Cosmas, Schneider, Jessica, Parkinson, John, Al-Garawi, Amal, Zhernakova, Alexandra, Gacesa, Ranko, Fu, Jingyuan, Weersma, Rinse K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359577/ https://www.ncbi.nlm.nih.gov/pubmed/36958817 http://dx.doi.org/10.1136/gutjnl-2022-328048

Ejemplares similares

Whole exome sequencing analyses reveal gene–microbiota interactions in the context of IBD
por: Hu, Shixian, et al.
Publicado: (2021)

Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn’s Disease Exacerbations
por: Klaassen, Marjolein A Y, et al.
Publicado: (2019)

Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome
por: Bolte, Laura A, et al.
Publicado: (2021)

The Composition and Metabolic Potential of the Human Small Intestinal Microbiota Within the Context of Inflammatory Bowel Disease
por: Ruigrok, Renate A A A, et al.
Publicado: (2021)

Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
por: Holmstroem, Rikke Boedker, et al.
Publicado: (2022)

Point-of-care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic
por: Jere, Mwansa, et al.
Publicado: (2021)

Patient attitudes towards faecal sampling for gut microbiome studies and clinical care reveal positive engagement and room for improvement
por: Bolte, Laura A., et al.
Publicado: (2021)

Ulcerative colitis increases risk of hypertension in a UK biobank cohort study
por: He, Jinshen, et al.
Publicado: (2022)

Gut microbiota in inflammatory bowel diseases: moving from basic science to clinical applications
por: Collij, Valerie, et al.
Publicado: (2020)

The emerging role of the small intestinal microbiota in human health and disease
por: Ruigrok, Renate A. A. A., et al.
Publicado: (2023)

Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease
por: Bangma, Amber, et al.
Publicado: (2020)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT‐TOPIC trial after 1‐year follow‐up
por: Lansdorp, Corine A., et al.
Publicado: (2022)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

TNFα inhibitors exacerbate Mycobacterium paratuberculosis infection in tissue culture: a rationale for poor response of patients with Crohn’s disease to current approved therapy
por: Qasem, Ahmad, et al.
Publicado: (2018)

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
por: Kiesslich, R, et al.
Publicado: (2011)

Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis
por: Aherne, Carol M, et al.
Publicado: (2011)

A pilot feasibility trial of cognitive–behavioural therapy for insomnia in people with inflammatory bowel disease
por: Salwen-Deremer, Jessica K, et al.
Publicado: (2021)

Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease
por: Qasem, Ahmad, et al.
Publicado: (2019)

Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes
por: Jansen, Fenna M, et al.
Publicado: (2020)

Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse
por: Robinson, A, et al.
Publicado: (2013)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease
por: Koelink, Pim J, et al.
Publicado: (2014)

Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn's disease
por: Manon‐Jensen, T., et al.
Publicado: (2021)

Discrepancy between patient‐ and healthcare provider‐reported adverse drug reactions in inflammatory bowel disease patients on biological therapy
por: Thomas, Pepijn W. A., et al.
Publicado: (2021)

Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
por: Cani, P D, et al.
Publicado: (2009)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Polygenic risk score predicts risk of primary sclerosing cholangitis in inflammatory bowel disease
por: Wang, Ming-Hsi, et al.
Publicado: (2023)

Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes
por: Christodoulou, Katja, et al.
Publicado: (2013)

Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome
por: Ruiz, Pedro A, et al.
Publicado: (2017)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
por: Feagan, B. G., et al.
Publicado: (2016)

Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism
por: Oancea, I, et al.
Publicado: (2017)

Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study
por: Sebastian, Shaji, et al.
Publicado: (2022)

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2013)

Changing nationwide trends in endoscopic, medical and surgical admissions for inflammatory bowel disease: 2003–2013
por: Ahmad, Ahmir, et al.
Publicado: (2018)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g8ctmv7iian6mmv33j8q9sro81